GlassScriptPhysician profile
Darren L Hirsch
NPI 1548498819
$5,520.91
in general payments reported to CMS, 2019-2025
27 companies · $833 in 2025
The $833 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $594 · 2021: $726 · 2022: $921 · 2023: $677 · 2024: $729 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,316.30 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,127.82 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $681.77 | 2019-2025 | |
| Alk-Abello, INC | $434.30 | 2019-2025 | Grastek, Ragwitek, Odactra |
| Regeneron Healthcare Solutions, INC. | $379.15 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $196.78 | 2019-2025 | |
| Kaleo, INC. | $194.84 | 2019-2024 | Auvi-Q |
| Amgen INC. | $188.11 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $126.46 | 2021-2024 | Eohilia |
| Leo Pharma INC. | $115.50 | 2022 | |
| Optinose US, INC. | $113.08 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $88.45 | 2021-2022 | |
| Lilly USA, LLC | $63.18 | 2024-2025 | Ebglyss, Zepbound, Mounjaro |
| Genentech USA, INC. | $62.85 | 2024-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $59.52 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $56.05 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $53.78 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $53.61 | 2022-2025 | Ryaltris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.93 | 2020-2021 | |
| Phadia US INC. | $31.56 | 2021-2024 | Immunocap |
| Abbvie INC. | $27.59 | 2023 | |
| Biocryst US Sales Co., LLC | $19.57 | 2024 | Orladeyo |
| Paratek Pharmaceuticals, INC. | $19.37 | 2025 | Xhance |
| Aimmune Therapeutics, INC. | $17.35 | 2021 | |
| Merck Sharp & Dohme LLC | $16.94 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.93 | 2021 | |
| Pfizer INC. | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.